Clinical Trial Update: Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating transfusion of INTERCEPT pathogen-reduced red blood cells in subjects with or without pre-existing antibodies to INTERCEPT RBCs; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Transfusion Reaction

Drugs mentioned

• INTERCEPT Pathogen Reduced Red Blood Cells

Snippet

Sponsor: Cerus Corporation | Conditions: Transfusion Reaction, Hemolytic | Phase 2 | Status: NOT_YET_RECRUITING